EUVIMEDEUVIMED entdecken
Crossref

Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening

Run Cui, Hao Duan, Wanming Hu, Chang Li, Sheng Zhong, Lun Liang, Siyu Chen, Hongrong Hu, Zhenqiang He, Zhenning Wang, Xiaoyu Guo, Zexin Chen und 8 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Run Cui und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer,…. Hauptthemen laut MEDLINE: Organoids, Neuroendocrine Tumors, Pituitary Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Beijing CSCO Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Precision medicine for pituitary neuroendocrine tumors (PitNETs) is limited by the lack of reliable research models.

Objective

To generate patient-derived organoids (PDOs), which could serve as a platform for personalized drug screening for PitNET patients.

Design

From July 2019 to May 2022, a total of 32 human PitNET specimens were collected for the establishment of organoids with an optimized culture protocol.

Setting

This study was conducted at Sun Yat-Sen University Cancer Center. Patients PitNET patients who were pathologically confirmed were enrolled in this study.

Interventions

Histological staining and whole-exome sequencing were utilized to confirm the pathologic and genomic features of PDOs. A drug response assay on PDOs was also performed. Main Outcome Measures PDOs retained key genetic and morphological features of their parental tumors.

Results

PDOs were successfully established from various types of PitNET samples with an overall success rate of 87.5%. Clinical nonfunctioning PitNETs-derived organoids (22/23, 95.7%) showed a higher likelihood of successful generation compared to those from functioning PitNETs (6/9, 66.7%). Preservation of cellular structure, subtype-specific neuroendocrine profiles, mutational features, and tumor microenvironment heterogeneity from parental tumors was observed. A distinctive response profile in drug tests was observed among the organoids from patients with different subtypes of PitNETs. With the validation of key characteristics from parental tumors in histological, genomic, and microenvironment heterogeneity consistency assays, we demonstrated the predictive value of the PDOs in testing individual drugs.

Conclusion

The established PDOs, retaining typical features of parental tumors, indicate a translational significance in innovating personalized treatment for refractory PitNETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsNeuroendocrine TumorsPituitary NeoplasmsAntineoplastic AgentsHumansFemaleMaleMiddle AgedAdultPilot ProjectsPrecision MedicineDrug Screening Assays, AntitumorAgedYoung AdultExome SequencingDrug Evaluation, Preclinical

Stichwörter der Autor:innen

organoidspharmaco-transcriptomicspituitary neuroendocrine tumors

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, S Yat-Sen University Cancer Center, Guangzhou, 510060 Guangdong, Chin…
  • Department of Neurosurgery, Guangdong 2nd Provincial Peoples Hospital, Guangzhou, 523058 Guangdong, China.
  • Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510000 Guangdong, China.
  • Department of Neurosurgery, Dongguan People's Hospital, Dongguan, 523058 Guangdong, China.
  • Department of Neurosurgery, First Affiliated Hospital of Ji'nan University, Guangzhou, 510630 Guangdong, China.
  • Guangdong Research Center of Organoid Engineering and Technology, Guangzhou, 510320 Guangdong, China.

ORCID-Profile: Chengcheng Guo, Yonggao Mou, Xiaobing Jiang

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Beijing CSCO Clinical Oncology Research Foundation

Zitieren

APA

Cui, R., Duan, H., Hu, W., Li, C., Zhong, S., Liang, L., Chen, S., Hu, H., He, Z., Wang, Z., Guo, X., Chen, Z., Xu, C., Zhu, Y., Chen, Y., Sai, K., Yang, Q., Guo, C., Mou, Y., & Jiang, X. (2025). Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae228

Vancouver

Cui R, Duan H, Hu W, Li C, Zhong S, Liang L, et al. Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae228

BibTeX
@article{Cui2025,
  author = {Cui, Run and Duan, Hao and Hu, Wanming and Li, Chang and Zhong, Sheng and Liang, Lun and Chen, Siyu and Hu, Hongrong and He, Zhenqiang and Wang, Zhenning and Guo, Xiaoyu and Chen, Zexin and Xu, Cong and Zhu, Yu and Chen, Yinsheng and Sai, Ke and Yang, Qunying and Guo, Chengcheng and Mou, Yonggao and Jiang, Xiaobing},
  title = {Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae228}
}
Kostenlos starten →